This article was originally published in The Gray Sheet
Large-scale manufacturing of the non-invasive glucose monitoring system's consumable AutoSensor component by supplier Corium gains FDA approval via PMA supplement, Cygnus announces Aug. 7. The company plans to perform final assembly of the wristwatch-like monitor at its own manufacturing facility to reduce costs, and plans to file a related PMA supplement. The device was approved in March and a full-scale launch is expected by year-end (1"The Gray Sheet" March 26, 2001, p. 13)
You may also be interested in...
Cygnus plans to kick off a pilot marketing program in April targeting 100-150 Type 1 diabetes patients to gauge firsthand consumer experience with the GlucoWatch Biographer. The non-invasive glucose monitoring system was approved by FDA on March 22.
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.